Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Cellectis S.A. - American Depositary Shares (CLLS)
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
cellectis.com/en/investors
Company Research
Source: GlobeNewswire
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA. The data are presented in a poster: CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN-edited allogeneic CAR T-cells without associated IL-2 toxicity Presenter: Shipra Das, Ph.D., Associate Director Immuno-Oncology, at Cellectis. Date/Time: February 25, 2025, 1:45-4:45 p.m. PT Session: Poster Session B CAR T-cell therapies have transformed the
Show less
Read more
Impact Snapshot
Event Time:
CLLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLLS alerts
High impacting Cellectis S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CLLS
News
- Cellectis Announces Arbitral Decision in Dispute with Servier [Yahoo! Finance]Yahoo! Finance
- Cellectis Announces Arbitral Decision in Dispute with ServierGlobeNewswire
- ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHLGlobeNewswire
- Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem CellsGlobeNewswire
- Cellectis GAAP EPS of $0.01 beats by $0.24, revenue of $37.16M [Seeking Alpha]Seeking Alpha
CLLS
Earnings
- 3/13/25 - Miss
CLLS
Sec Filings
- 12/15/25 - Form 6-K
- 12/12/25 - Form SCHEDULE
- 12/8/25 - Form 6-K
- CLLS's page on the SEC website